nuclear pore complex interacting protein family member B15Genealiases: A-761H5.4 · NPIPL2
Q-omics provides the consensus-scored NPIPB15 profile across patient tissues and cancer cell-line models. NPIPB15 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, NPIPB15 is differentially expressed in 4, with the highest sampling consensus in LIHC. Additionally, NPIPB15 RNA expression shows 6,611 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight DLBC, LIHC, and KIRC as cancer lineages where NPIPB15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPIPB15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPIPB15 survival associations across molecular data types. NPIPB15 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPIPB15 RNA expression–survival associations across cancer types. High NPIPB15 expression shows unfavorable associations in DLBC, ACC, ESCA, LGG, READ and BRCA. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify DLBC as the clearest survival context for NPIPB15 RNA expression.
This table summarizes NPIPB15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for NPIPB15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPIPB15 shows lower tumor expression in STAD and higher tumor expression in LIHC, KIRC and READ. The LIHC box plot shows higher NPIPB15 RNA expression in tumor versus normal tissue (log2 FC = +0.418, t-test p = .041).
This table shows molecular features associated with NPIPB15 in patient tissues and cancer cell lines. In patient samples, NPIPB15 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set. In cancer cell lines, NPIPB15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
